Cargando…
Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial
IMPORTANCE: Decipher (Decipher Biosciences Inc) is a genomic classifier (GC) developed to estimate the risk of distant metastasis (DM) after radical prostatectomy (RP) in patients with prostate cancer. OBJECTIVE: To validate the GC in the context of a randomized phase 3 trial. DESIGN, SETTING, AND P...
Autores principales: | Feng, Felix Y., Huang, Huei-Chung, Spratt, Daniel E., Zhao, Shuang (George), Sandler, Howard M., Simko, Jeffry P., Davicioni, Elai, Nguyen, Paul L., Pollack, Alan, Efstathiou, Jason A., Dicker, Adam P., Todorovic, Tamara, Margrave, Jennifer, Liu, Yang (Seagle), Dabbas, Bashar, Thompson, Darby J. S., Das, Rajdeep, Dignam, James J., Sweeney, Christopher, Attard, Gerhardt, Bahary, Jean-Paul, Lukka, Himanshu R., Hall, William A., Pisansky, Thomas M., Shah, Amit B., Pugh, Stephanie L., Shipley, William U., Tran, Phuoc T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879385/ https://www.ncbi.nlm.nih.gov/pubmed/33570548 http://dx.doi.org/10.1001/jamaoncol.2020.7671 |
Ejemplares similares
-
Serum testosterone changes in patients treated with radiation therapy alone for prostate cancer on NRG oncology RTOG 9408
por: Nichols, R. Charles, et al.
Publicado: (2017) -
Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415
por: Khairnar, Rahul, et al.
Publicado: (2021) -
Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825
por: Scheurer, Michael E, et al.
Publicado: (2022) -
Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825
por: Patil, Nirav, et al.
Publicado: (2021) -
NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma
por: Batchelor, Tracy T, et al.
Publicado: (2023)